Paul Ibukunoluwa Oyediran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul Ibukunoluwa Oyediran has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Busayo Adetunji
Department of Medicine, Ladoke Akintola University of Technology , Ogbomoso
1 shared publication - Chukwunonso Emmanuel Chukwumaeze
Department of Medicine, University of Nigeria Teaching Hospital , Ituku Ozalla
1 shared publication - Elizabeth Olufunke Oke
Department of Chemical Pathology University of Osun Teaching Hospital, Osogbo, Osun State, Nigeria
1 shared publication - Emmanuel Kolawole Oluwumi
Department of Medicine, Ladoke Akintola University of Technology , Ogbomoso
1 shared publication - Eromo Kokogho
Department of Medicine, Federal Teaching Hospital , Ido-Ekiti
1 shared publication - James Ayokunle Balogun
Division of Neurosurgery, Department of Surgery, College of Medicine, University of Ibadan , Ibadan
1 shared publication
Latest Publications
- Open Access
- 1 April 2025
- Published by IK Press in Journal of Disease and Global Health
- Vol. 18 (2) , 170-180
Weight Loss Drug Therapies: Current Evidence and Prospects for Use in Metabolic Clinics in Nigeria
Obesity is a major risk factor for cardiovascular diseases, type 2 diabetes, and other chronic illnesses. There are approximately 21 million overweight and obese people in Nigeria over the age of 15, with corresponding age-adjusted prevalence rates of 20.3% and 11.6% respectively. It is recommended that patients with a body mass index (BMI) of at least 30kg/m2 or those with comorbidities related to obesity and a BMI of at least 27kg/m2 will benefit from weight-loss medications. Although dietary and activity changes are still essential components of weight loss strategies, medications are seen as an additional treatment when lifestyle changes are not enough to reach weight loss objectives. Typically, pharmacotherapy for obesity focuses on pathways related to energy metabolism, appetite control, and fat storage. Recently, the dual glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1R agonist, (Tirzepatide) has shown improved weight loss compared to selective GLP-1R agonists in patients with T2DM. Glucagon, similar in structure to GLP-1 and GIP, was incorporated into the duos to form a single chimera peptide (Retatrudide) and the trio hormones are recognized by their three separate receptors. Given the benefits of the dual GIPR and GLP-1R agonist, tirzepatide, a triple agonist retatrudide, targeting all 3 receptors, has the potential to provide a therapeutic approach with superior glycemic control and weight loss than what has been achieved with single and dual receptor agonists. This report is a literature review of existing research or reports on obesity or overweight or anti-obesity drug or weight loss drugs, aim to explore the evolution of weight-loss drugs, revolutionary novel therapies, and the need for their general acceptability in developing countries like Nigeria. Databases of PubMed, Google Scholar, and ResearchGate were searched to identify relevant articles published up to recent. The search terms were obesity OR pharmacotherapy for obesity OR weight loss drugs OR novel weight management drugs. The use of medications for the management of obesity is a subject of continuing research and clinical interest. Despite breakthrough discoveries of novel medications with minimal side effects but have limited adoption in low- and middle-income countries.
- 1 April 2025
- Published by IK Press in Journal of Disease and Global Health
- Vol. 18 (2) , 170-180
Open AccessWeight Loss Drug Therapies: Current Evidence and Prospects for Use in Metabolic Clinics in Nigeria
Obesity is a major risk factor for cardiovascular diseases, type 2 diabetes, and other chronic illnesses. There are approximately 21 million overweight and obese people in Nigeria over the age of 15, with corresponding age-adjusted prevalence rates of 20.3% and 11.6% respectively. It is recommended that patients with a body mass index (BMI) of at least 30kg/m2 or those with comorbidities related to obesity and a BMI of at least 27kg/m2 will benefit from weight-loss medications. Although dietary and activity changes are still essential components of weight loss strategies, medications are seen as an additional treatment when lifestyle changes are not enough to reach weight loss objectives. Typically, pharmacotherapy for obesity focuses on pathways related to energy metabolism, appetite control, and fat storage. Recently, the dual glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1R agonist, (Tirzepatide) has shown improved weight loss compared to selective GLP-1R agonists in patients with T2DM. Glucagon, similar in structure to GLP-1 and GIP, was incorporated into the duos to form a single chimera peptide (Retatrudide) and the trio hormones are recognized by their three separate receptors. Given the benefits of the dual GIPR and GLP-1R agonist, tirzepatide, a triple agonist retatrudide, targeting all 3 receptors, has the potential to provide a therapeutic approach with superior glycemic control and weight loss than what has been achieved with single and dual receptor agonists. This report is a literature review of existing research or reports on obesity or overweight or anti-obesity drug or weight loss drugs, aim to explore the evolution of weight-loss drugs, revolutionary novel therapies, and the need for their general acceptability in developing countries like Nigeria. Databases of PubMed, Google Scholar, and ResearchGate were searched to identify relevant articles published up to recent. The search terms were obesity OR pharmacotherapy for obesity OR weight loss drugs OR novel weight management drugs. The use of medications for the management of obesity is a subject of continuing research and clinical interest. Despite breakthrough discoveries of novel medications with minimal side effects but have limited adoption in low- and middle-income countries.
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdaf195
Trends of hospital-based reporting of intracranial neoplasms in Nigeria from 1960 to 2024: A systematic review and pooled analysis of literatures
Background: Intracranial neoplasms, encompassing benign and malignant tumors, remain a significant health concern worldwide. This review systematically examines hospital-based reports of intracranial neoplasms in Nigeria from 1960 to July 2024, highlighting their distribution, demographics, and temporal trends. Methods: Following PRISMA guidelines, studies published from 1960 onward were identified through PubMed, Google Scholar, and African Journals Online. Eligible studies reported incidence, prevalence, or demographic data of intracranial neoplasms in Nigeria. Extracted data were pooled for meta-analysis to estimate aggregated incidence and prevalence. Results: Forty-five studies comprising 3517 cases were included. Pooled extrapolated prevalence was 3.22 (95% CI: 1.66-5.22), while compounded 10 yearly incidence was 3.66 (95% CI: 1.67-6.32). Reported incidence increased from 2.18% (1960-1969) to 4.08% (2000-2009) and 4.84% (2010-2019). Gliomas, meningiomas, and pituitary adenomas were the most frequent tumors. Among adults, meningioma predominated, followed by glioma and pituitary adenoma, whereas in children, gliomas were most common, followed by medulloblastoma and craniopharyngioma. Male predominance was observed (male-to-female ratio 1.17:1), with peak cases in the fourth to sixth decades. Regionally, southern Nigeria (southeast and southwest) showed higher incidence, reflecting disparities in diagnostic capacity and reporting compared with the north. Conclusion: Reported intracranial neoplasms in Nigeria have increased over the decades, with a prevalence of 3.22 and distinct demographic and geographic patterns. Strengthening diagnostic infrastructure, improving reporting systems, and establishing a national registry are essential for better understanding and management.
- 6 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdaf195
Open AccessTrends of hospital-based reporting of intracranial neoplasms in Nigeria from 1960 to 2024: A systematic review and pooled analysis of literatures
Background: Intracranial neoplasms, encompassing benign and malignant tumors, remain a significant health concern worldwide. This review systematically examines hospital-based reports of intracranial neoplasms in Nigeria from 1960 to July 2024, highlighting their distribution, demographics, and temporal trends. Methods: Following PRISMA guidelines, studies published from 1960 onward were identified through PubMed, Google Scholar, and African Journals Online. Eligible studies reported incidence, prevalence, or demographic data of intracranial neoplasms in Nigeria. Extracted data were pooled for meta-analysis to estimate aggregated incidence and prevalence. Results: Forty-five studies comprising 3517 cases were included. Pooled extrapolated prevalence was 3.22 (95% CI: 1.66-5.22), while compounded 10 yearly incidence was 3.66 (95% CI: 1.67-6.32). Reported incidence increased from 2.18% (1960-1969) to 4.08% (2000-2009) and 4.84% (2010-2019). Gliomas, meningiomas, and pituitary adenomas were the most frequent tumors. Among adults, meningioma predominated, followed by glioma and pituitary adenoma, whereas in children, gliomas were most common, followed by medulloblastoma and craniopharyngioma. Male predominance was observed (male-to-female ratio 1.17:1), with peak cases in the fourth to sixth decades. Regionally, southern Nigeria (southeast and southwest) showed higher incidence, reflecting disparities in diagnostic capacity and reporting compared with the north. Conclusion: Reported intracranial neoplasms in Nigeria have increased over the decades, with a prevalence of 3.22 and distinct demographic and geographic patterns. Strengthening diagnostic infrastructure, improving reporting systems, and establishing a national registry are essential for better understanding and management.